The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial and/or institutional partners, in order to serve the patient needs and for the benefit of the society, as well as to contribute to sustainability of the Institut Pasteur’s resources.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
Gates millions for vaccine research The fight against hepatitis C and HIV: foundation supports international consortium
The Bill and Melinda Gates Foundation (Seattle, USA) has decided to fund an international research consortium led by the German Research Centre of Biotechnology (GBF) in Braunschweig and the Institut Pasteur in Paris. The long-term goal of the 9 million dollar project is the development of vaccines against Hepatitis C and HIV.
Paris, june 28, 2005
“The grant is for us a singular success”, says Prof. Dr. Rudi Balling, scientific director of the GBF and the German project leader. Initially, more than 1500 ideas from 75 countries were submitted; grants were finally awarded to just 43 projects.“Our proposal demonstrates the power of intelligent collaboration”, comments Dr. James Di Santo, director of the Immunol-ogy Department at the Institut Pasteur and the project head in France. “Each participant is a recognized leader in his domain; the decision to put our strengths together towards an inno-vative project will help us tackle the difficult problem of vaccines for HCV and HIV.” Par-ticularly gratifying, says Balling, is that only research establishments with the highest inter-national reputations are participating in the consortium, which in addition to the GBF and Institut Pasteur, includes the German Medical School in Hanover, the University of Amster-dam, the Necker Hospital in Paris and New York’s Rockefeller University.
The project tackles one of the most urgent health problems in countries of the developing world, where most of the 170 million people infected with the hepatitis C virus (HCV) live. Those affected often die as a result of liver cirrhosis or cancer of the liver. The most efficient way of fighting HCV would be mass vaccinations with an effective and easily used vaccine. However, the development of such a vaccine faces a number of major obstacles. For example, every vaccine, before it can be used on humans, must be tested on animals, but for HCV this is currently not possible: the most suitable experimental animal, the mouse, is naturally immune to the virus, which propagates itself in human liver cells.
The consortium will attempt to get around the problem by implanting human liver and im-mune cells into mice. If successful, it should be possible to infect these animals with HCV and study the reaction of potential vaccines, thus opening up the possibility of saving mil-lions of human lives from the deadly consequences of hepatitis C infection. Mice carrying a human immune system will also be used for testing vaccines against HIV, the AIDS virus.
The Bill and Melinda Gates Foundation and the cooperation partners
The Bill & Melinda Gates Foundation works to promote greater equity in four areas: global health, education, public libraries, and support for at-risk families in Washington state and Oregon in the U.S. The Seattle-based foundation joins local, national, and international partners to ensure that advances in these areas reach those who need them most. The foun-dation is led by Bill Gates’ father, William H. Gates Sr., and Patty Stonesifer, and has an endowment of approximately $28 billion.